繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 抗肿瘤药 >> 药品目录 >> 化疗类 >> 植物类 >> 甲磺酸艾日布林注射剂|Halaven(eribulin mesylate)

甲磺酸艾日布林注射剂|Halaven(eribulin mesylate)

2011-04-20 16:52:53  作者:新特药房  来源:中国新特药网天津分站  浏览次数:620  文字大小:【】【】【
简介: 制造商: 卫材制药 药理分类: 抗肿瘤剂(非紫杉烷类抑制剂微管的动态)。 活性成分(补): Eribulin甲磺酸为0.5mg/ml,静脉注射解决方案 指示(补): 治疗对谁曾接受至少两个转移性疾病患者化疗 ...

制造商:
卫材制药

药理分类:
抗肿瘤剂(非紫杉烷类抑制剂微管的动态)。

活性成分(补):
Eribulin甲磺酸为0.5mg/ml,静脉注射解决方案
指示(补):
治疗对谁曾接受至少两个转移性疾病患者化疗方案治疗转移性乳腺癌。之前的治疗应包括一种anthracycline和无论是在辅助或转移设置紫杉。

药理作用:
Eribulin甲磺酸是对Halichondria okadai,发现了一个海绵物质合成类似物。它是一个非紫杉烷类抑制剂,抑制微管的动态不影响微管缩短阶段的生长阶段。它也吸收了多余微管蛋白聚合成非生产性。它的微管蛋白为基础的抗有丝分裂机制导致的G2 / M细胞周期阻滞,有丝分裂纺锤体的破坏,最终,经过长时间的有丝分裂阻断细胞凋亡。

Eribulin没有显着代谢,主要是消除粪便不变。

临床试验:
研究一比较eribulin以及在开放标签随机,单剂疗法,多中心试验,涉及762转移性乳腺癌谁收到了转移性疾病至少两个疗程的化疗,并在6个月,他们最后的化疗方案的病人病情恶化。分层随机是地理上,由以前的HER2/neu地位和卡培他滨曝光。对照组97%,分别接受化疗(如长春瑞滨26%,18%吉西他滨,卡培他滨18%,16%紫杉,蒽环类9%,10%其他化疗)或3%的荷尔蒙治疗。主要功效结果是整体存活率。整体存活显着改善被认为在给定eribulin(13.1个月),与对照组(10.6个月)患者。

法律分类:
接收

成人:
通过静脉注射给了2-5分钟。 1.4mg/m2的日子1和21天的周期8。轻度肝功能不佳(Child - Pugh A级)或中度肾功能损害(肌酐清除率30-50mL/min):1.1mg/m2的天1和21天的周期8。中度肝功能受损(Child - Pugh分级乙):0.7mg/m2的天1和21天的周期8。持有非国大<1000/mm3剂量,血小板<75000/mm3,或3或4级非血液学毒性。延迟或减少剂量根据毒性;见文献。不要重新升级后,剂量减少。

儿童:
<18年:不推荐。

警告/注意事项:
监视器CBCs,加大监测,如果3级或4血细胞减少的发展,推迟和减少,如果发热性中性粒或4级中性粒细胞减少持久> 7天以后的剂量开发频率。外周神经病变监控;扣3级或4如果周围神经病变的发展,直到第2等级​​或更低的剂量。先天性长QT综合征:避免。瑞士法郎,缓慢性心律失常,电解质异常:监测心电图QT间期延长。纠正电解质异常(钾,镁+)治疗前,监测。严重肝功能不全(Child - Pugh分级C)或严重肾功能损害(肌酐清除率<30mL/min):没有足够的数据。妊娠(Cat.D),哺乳期妇女:不推荐。

互动(补):
警告说,与其他药物延长QT间隔(例如,IA类抗心律失常药和三)监测。

不良反应(补):
白细胞减少,贫血,乏力/疲劳,脱发,周围神经病变,恶心,便秘,发热性中性粒细胞减少;可能的QT间期延长,肝酶升高。

注释:
切勿与葡萄糖含解决方案。不要在其他管理药物或液体的同一行。

如何提供:
单用小瓶(液2mL)-1

最后更新:
2011年2月10号

Manufacturer:

Eisai Pharmaceuticals

Pharmacological Class:

Antineoplastic agent ­(non-taxane microtubule dynamics inhibitor).

Active Ingredient(s):

Eribulin mesylate 0.5mg/mL, solution for IV injection.

Indication(s):

Treatment of metastatic breast cancer in patients who have previously received at least two chemotherapeutic regimens for metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

Pharmacology:

Eribulin mesylate is a synthetic analogue of a substance found in Halichondria okadai, a marine sponge. It is a non-taxane ­microtubule dynamics inhibitor that inhibits the growth phase of microtubules without ­affecting the shortening phase. It also sequesters tubulin into nonproductive aggregates. Its tubulin-based antimitotic mechanism leads to G2/M cell-cycle block, disruption of mitotic spindles and, ultimately, apoptotic cell death after prolonged mitotic blockage.

Eribulin is not significantly metabolized and is primarily eliminated unchanged in the feces.

Clinical Trials:

Study 1 compared eribulin and single-agent therapy in an open-label, randomized, multicenter trial involving 762 patients with metastatic breast cancer who had received at least two chemotherapeutic regimens for metastatic disease and had disease progression within 6 months of their last chemotherapy regimen. Randomization was stratified geo­graph­ically, by HER2/neu status and prior capecita­bine exposure. The control group received either 97% chemotherapy (eg, 26% vinorelbine, 18% gemcitabine, 18% capecitabine, 16% taxane, 9% anthracycline, 10% other chemotherapy) or 3% hormonal therapy. The main efficacy outcome was overall survival. A statis­tically ­significant improvement in overall survival was seen in the patients given eribulin (13.1 months) compared with the control group (10.6 months).

Legal Classification:

Rx

Adults:

Give by IV injection over 2–5 minutes. 1.4mg/m2 on Days 1 and 8 of a 21-day cycle. Mild hepatic impairment (Child-Pugh A) or moderate renal impairment (CrCl 30–50mL/min): 1.1mg/m2 on Days 1 and 8 of a 21-day cycle. Moderate hepatic impairment (Child-Pugh B): 0.7mg/m2 on Days 1 and 8 of a 21-day cycle. Hold dose for ANC <1000/mm3, platelets <75000/mm3, or grade 3 or 4 non-hematological toxicities. Delay or reduce dose according to toxicities; see literature. Do not re-escalate dose after it is reduced.

Children:

<18 years: not recommended.

Warnings/Precautions:

Monitor CBCs; increase frequency of monitoring if grade 3 or 4 cyto­penias develop, delay and reduce subsequent doses if febrile neutropenia or grade 4 neutro­penia lasting >7 days develops. Monitor for peripheral neuropathy; withhold dose if grade 3 or 4 peripheral neuropathy develops until ­resolution to grade 2 or less. Congenital long QT syndrome: avoid. CHF, bradyarrhythmias, electrolyte abnormalities: monitor ECG for prolonged QT interval. Correct electrolyte abnormalities (K+, Mg+) before treatment; mon­itor. Severe hepatic impairment (Child-Pugh C) or severe renal impairment (CrCl<30mL/min): insufficient data. Pregnancy (Cat.D), nursing mothers: not recommended.

Interaction(s):

Caution with other drugs that prolong QT interval (eg, Class IA and III ­antiarrhythmics); monitor.

Adverse Reaction(s):

Neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, constipation, febrile neutropenia; possible QT prolongation, elevated liver enzymes.

Notes:

Do not mix with dextrose-containing solutions. Do not administer in same line as other drugs or fluids.

How Supplied:

Single-use vial (2mL)—1

责任编辑:admin


相关文章
新型抗癌药物-甲磺酸艾日布林注射剂
甲磺酸艾日布林注射剂(eribulin 商品名为Halaven)
 

最新文章

更多

· 长春新碱硫酸注射液(An...
· 紫杉醇注射液|GENEXOL P...
· 力扑素(注射用紫杉醇脂...
· 诺维本软胶囊|Navelbine...
· 能达(注射用硫酸长春新碱)
· 贞护春(注射用硫酸长春...
· 艾思奇(注射用异环磷酰胺)
· 振东(紫杉醇注射液)
· 多帕菲(多西他赛注射液)
· Jevtana(cabazitaxel)...

推荐文章

更多

· 长春新碱硫酸注射液(An...
· 紫杉醇注射液|GENEXOL P...
· 力扑素(注射用紫杉醇脂...
· 诺维本软胶囊|Navelbine...
· 能达(注射用硫酸长春新碱)
· 贞护春(注射用硫酸长春...
· 艾思奇(注射用异环磷酰胺)
· 振东(紫杉醇注射液)
· 多帕菲(多西他赛注射液)
· Jevtana(cabazitaxel)...

热点文章

更多